Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

JNJ 81201887

Next Previous
Drug Profile

JNJ 81201887

Alternative Names: AAVCAGsCD59; HMR59; JNJ-1887; JNJ-81201887

Latest Information Update: 03 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tufts University
  • Developer Hemera Biosciences; Johnson & Johnson Innovative Medicine
  • Class Eye disorder therapies; Gene therapies; Recombinant proteins
  • Mechanism of Action Complement system protein inhibitors; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Dry age-related macular degeneration
  • No development reported Wet age-related macular degeneration

Most Recent Events

  • 23 Feb 2026 Janssen Research & Development completes a phase II trial in Dry age-related macular degeneration (Combination therapy, In the elderly, In adults) in United Kingdom, Turkey, Switzerland, Sweden, Spain, Poland, Netherlands, Italy, Hungary, Germany, Denmark, Czech Republic, Canada, Belgium, Australia and USA (Intravitreous) (NCT05811351)
  • 28 Feb 2025 No recent reports of development identified for phase-I development in Wet age-related macular degeneration(In the elderly, In adults) in USA (Intravitreous, Injection)
  • 19 Sep 2024 Johnson & Johnson Innovative Medicine initiates phase-II clinical trials for Dry age-related macular degeneration (In the elderly, In adults) in USA (Intravitreous) (NCT06635148)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top